Step 1
Accelerating RNA
Therapeutics with AI
BetaKumiChem™ is an agentic AI platform for ASO and siRNA design: from target to ranked candidates, up to 200× faster, with the reasoning behind every pick.
LLM-Driven Drug Design
Start with a simple prompt
KumiChem™'s specialized agents design oligonucleotides end-to-end, fast, and show their reasoning at every step.
Illustrative exampleDesign siRNAs targeting MALAT1
Speed
200×faster than manual oligo design workflows
Interpretability
Insight behind every pick
Each ranking comes with the evidence that supports it, so your team can decide with confidence.
ScoreEvidenceDecision
Step 2
Binding Prediction Agent
Efficacy & off-target screeningStep 3
Structure Folding Agent
Secondary structure predictionStep 4
Optimization Agent
Chemical modifications5
Top candidates
Prioritized by efficacy, safety and IP clearance, ready for synthesis
Next: wet-lab validation
Candidates move on to in vitro testing with research partners
Backed by and working with
Therapeutic Focus
Where RNA therapeutics unlock new possibilities
Rare Disease
7,000+
rare diseases — about 95% have no approved treatment
Patients face rapid, life-threatening decline while effective treatments remain scarce or out of reach.
RNA approach
Target root genetic causes directly
Cardiometabolic
#1
cause of death worldwide
Millions face preventable heart attacks, strokes, and organ failure while long-term control remains inadequate.
RNA approach
Durable control with infrequent dosing
Oncology
~10M
cancer deaths every year
Many tumors are driven by "undruggable" mutations that traditional small-molecule therapies cannot reach.
RNA approach
Silence disease genes at their source
Neurology
55M+
people living with dementia
Neurodegenerative diseases progress relentlessly with limited options to modify underlying pathology.
RNA approach
Modulate disease pathways in the CNS
Sources: WHO; NIH Genetic and Rare Diseases Information Center; Global Genes.
Who It's For
Built for every team advancing RNA drug discovery,
from pharma R&D and academic labs to the clinic.
01
Pharma & Biotech
Accelerate ASO and siRNA programs from target assessment to candidate prioritization, with in silico toxicity screening built in.
02
Universities & Research Institutes
Bring AI into everyday research. Easy to adopt and flexible, KumiChem™ helps labs design, evaluate and iterate faster.
03
Hospitals & Clinical Research
Connect clinical insight with RNA therapeutics design, from exploring targets for rare and unmet diseases to assessing safety early.
04
Students & Learners
New to drug discovery or AI? Explore approachable resources on the latest in RNA therapeutics.
05
Data-Driven Decisions
Explore vast chemical and biological space, compare strategies, and get ranked, evidence-backed recommendations.
06
Fits Your Workflow
Plug into existing research processes and scale from a single experiment to a full portfolio.
07
Built for Collaboration
We already co-create with research labs and welcome partners through pilots, joint research and data collaboration.
08
Expert Support
Our drug discovery scientists and AI engineers support your team from onboarding to results.
Who It's For
Built for every team advancing RNA drug discovery, from pharma R&D and academic labs to the clinic.
01
Pharma & Biotech
Accelerate ASO and siRNA programs from target assessment to candidate prioritization, with in silico toxicity screening built in.
02
Universities & Research Institutes
Bring AI into everyday research. Easy to adopt and flexible, KumiChem™ helps labs design, evaluate and iterate faster.
03
Hospitals & Clinical Research
Connect clinical insight with RNA therapeutics design, from exploring targets for rare and unmet diseases to assessing safety early.
04
Students & Learners
New to drug discovery or AI? Explore approachable resources on the latest in RNA therapeutics.
05
Data-Driven Decisions
Explore vast chemical and biological space, compare strategies, and get ranked, evidence-backed recommendations.
06
Fits Your Workflow
Plug into existing research processes and scale from a single experiment to a full portfolio.
07
Built for Collaboration
We already co-create with research labs and welcome partners through pilots, joint research and data collaboration.
08
Expert Support
Our drug discovery scientists and AI engineers support your team from onboarding to results.
KumiChem™ offers an innovative approach to integrating AI into oligonucleotide drug discovery. Its unified platform has strong potential to accelerate siRNA and other oligonucleotide therapeutics development by streamlining molecular design, optimization, and evaluation.
Newsroom
News
Company news and product updates
ResearchJoint Study Poster Presentation at CBI 2026ResearchAttends OTS 2026 Annual Meeting in DenverEventDLeader Explores Collaboration Opportunities at BioJapan 2026EventDLeader Selected for J-StarX GSE Bootcamp with Berkeley SkyDeckEventDLeader Showcases KumiChem™ at TECHNIUM Global Conference 2026CompanyNikkei Biotech Features KumiChem™, DLeader’s AI Platform for RNA Drug DiscoveryResearchDLeader Publishes Mini Review on the Opportunities and Challenges of AI in RNA Drug DiscoveryCompanyQingwen Chen Featured in BIE Japan Participant StoryCompanyDLeader joins JETRO Global Acceleration Hub Boston programEventDLeader Pitches KumiChem™ at HVC KYOTO 2026, One of Japan’s Largest Healthcare Pitch EventsResearchPoster Presentation at NATSJ 2026AwardKumiChem™ Wins Best Potential Award at BIE Japan Workshop 2026CompanyDLeader Shares 2025 Milestones and 2026 Priorities on PR TIMESProduct updateKumiChem™ web beta now availableEventDLeader Pitches Global Vision for KumiChem™ at Techstars Tokyo 2025 Demo DayCompanyDr. Takeshi Yamada Joins DLeader as Scientific AdvisorPartnershipDLeader Initiates Joint Research with the Mizuguchi Laboratory at The University of OsakaCompanyDLeader Joins LINK-J to Expand Life Sciences CollaborationEventDLeader Introduces KumiChem™ at Global Startup EXPO 2025 Side EventEventPresenting at Impact Future Weekend at TIBEventPitched at Tech for Impact: HealthTech Startup Pitch EventAwardAnn Grishunova Wins Grand Prize in The University of Osaka’s OCTOPUS Rack Design ContestInvestmentDLeader Selected for Techstars Tokyo 2025, Secures US$120,000 in Pre-Seed FundingCompanySelected for HVC Kyoto 2025CompanyProfessor Kazuhiko Nakatani Joins DLeader as Scientific AdvisorEventDLeader Introduces KumiChem™ at Ibaraki Tech Planter Lightning TalkEventDLeader’s Message Selected for “Future Voyage” at Expo 2025 Osaka, KansaiCompanyProfessor Kenji Mizuguchi Joins DLeader as Scientific AdvisorInvestmentDLeader Secures ¥10 Million in Angel Investment to Pursue Its Vision for AI-Driven Drug DiscoveryCompanyDLeader Founded in Osaka to Advance AI-Driven Drug Discovery
Scroll for earlier news
FAQ
Frequently asked questions
Quick answers about KumiChem™, how it works and how to get started.
Design ASO and siRNA candidates from a simple prompt. KumiChem™'s agents handle target site selection, efficacy and off-target screening, structure analysis and chemical modification, then rank candidates with the evidence behind them.
Teams can also curate their own datasets and train custom models for program-specific needs.
KumiChem™ is built specifically for oligonucleotide drug discovery:
- End-to-end agents. One workflow from target to ranked candidates, instead of separate tools.
- Interpretable results. Every ranking is linked to its evidence: structure, off-targets, literature and patents.
- Proprietary data. 100K+ curated toxicity and chemical modification datapoints.
- Built by scientists. Developed by a team of RNA and AI researchers.
RNA therapeutics teams at pharma and biotech companies, academic labs, and hospital and clinical research groups exploring nucleic acid medicines.
Yes. KumiChem™ supports curating your internal datasets and training custom models on them. Data handling and deployment are agreed with each team.
KumiChem™ is in beta and works at the in silico design stage. We're running wet-lab validation with research partners and share results as they become available.
We onboard teams through demos and pilot projects. Book a demo to see KumiChem™ on your own target, or talk to us about becoming a PoC partner.
Still have questions?
Send us your question and our team will reply by email.
Book a demo
Accelerate your RNA research with KumiChem™
Tell us about your team and program. We'll set up a demo and can discuss pilots or research collaboration.